Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Medical Specialties (25)
- Internal Medicine (11)
- Epidemiology (10)
- Medical Sciences (6)
- Diseases (5)
-
- Emergency Medicine (4)
- Social and Behavioral Sciences (4)
- Obstetrics and Gynecology (3)
- Sociology (3)
- Clinical Epidemiology (2)
- Infectious Disease (2)
- Life Sciences (2)
- Maternal and Child Health (2)
- Medical Genetics (2)
- Medicine and Health (2)
- Mental and Social Health (2)
- Oncology (2)
- Otolaryngology (2)
- Otorhinolaryngologic Diseases (2)
- Pathological Conditions, Signs and Symptoms (2)
- Surgery (2)
- Women's Health (2)
- Bioethics and Medical Ethics (1)
- Bioinformatics (1)
- Biomedical Informatics (1)
- Community Health (1)
- Community Health and Preventive Medicine (1)
- Institution
Articles 31 - 31 of 31
Full-Text Articles in COVID-19
Canakinumab To Reduce Deterioration Of Cardiac And Respiratory Function In Sars-Cov-2 Associated Myocardial Injury With Heightened Inflammation (Canakinumab In Covid-19 Cardiac Injury: The Three C Study), Tom Kai Ming Wang, Prabalini Rajendram, Abhijit Duggal, A Michael Lincoff, Steven E Nissen, Venu Menon, Paul C Cremer
Canakinumab To Reduce Deterioration Of Cardiac And Respiratory Function In Sars-Cov-2 Associated Myocardial Injury With Heightened Inflammation (Canakinumab In Covid-19 Cardiac Injury: The Three C Study), Tom Kai Ming Wang, Prabalini Rajendram, Abhijit Duggal, A Michael Lincoff, Steven E Nissen, Venu Menon, Paul C Cremer
Faculty, Staff and Student Publications
BACKGROUND: In patients with Covid-19, myocardial injury and increased inflammation are associated with morbidity and mortality. We designed a proof-of-concept randomized controlled trial to evaluate whether treatment with canakinumab prevents progressive respiratory failure and worsening cardiac dysfunction in patients with SARS-CoV2 infection, myocardial injury, and high levels of inflammation.
HYPOTHESIS: The primary hypothesis is that canakiumab will shorten time to recovery.
METHODS: The three C study (canakinumab in Covid-19 Cardiac Injury, NCT04365153) is a double-blind, randomized controlled trial comparing canakinumab 300 mg IV, 600 mg IV, or placebo in a 1:1:1 ratio in hospitalized Covid-19 patients with elevations in troponin …